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Background: Statin use after colorectal cancer diagnosis may improve survival but evidence from observational studies is
conflicting. The anti-cancer effect of statins may be restricted to certain molecular subgroups. In this population-based cohort
study, the interaction between p53 and 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGCR) expression, KRAS mutations,
and the association between statin use and colon cancer survival was assessed.
Methods: The cohort consisted of 740 stage II and III colon cancer patients diagnosed between 2004 and 2008. Statin use was
determined through clinical note review. Tissue blocks were retrieved to determine immunohistochemical expression of p53 and
HMGCR in tissue microarrays and the presence of KRAS mutations in extracted DNA. Cox proportional hazards models were used
to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for colorectal cancer-specific and overall survival.
Results: Statin use was not associated with improved cancer-specific survival in this cohort (HR¼ 0.91, 95% CI 0.64–1.28). Statin use
was also not associated with improved survival when the analyses were stratified by tumour p53 (wild-type HR¼ 1.31, 95% CI 0.67–
2.56 vs aberrant HR¼ 0.80, 95% CI 0.52–1.24), HMGCR (HMGCR-high HR¼ 0.69, 95% CI 0.40–1.18 vs HMGCR-low HR¼ 1.10, 95%
CI 0.66–1.84), and KRAS (wild-type HR¼ 0.73, 95% CI 0.44–1.19 vs mutant HR¼ 1.21, 95% CI 0.70–2.21) status.
Conclusions: Statin use was not associated with improved survival either independently or when stratified by potential mevalonate
pathway biomarkers in this population-based cohort of colon cancer patients.
Statins are commonly prescribed lipid lowering medications that
inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme-A
reductase (HMGCR) (Ng et al, 2011). In addition to their
cholesterol-lowering action, they may have pleiotropic anti-cancer
effects through inhibition of the mevalonate pathway (Bardou et al,
2010; Thurnher et al, 2012). However, observational data assessing
the association between post-diagnostic statin use and colorectal
cancer survival lacks consistency (Ng et al, 2011; Mace et al, 2013;
Cardwell et al, 2014a; Krens et al, 2014; Hoffmeister et al, 2015;
Kim et al, 2015; Lim et al, 2015; Zanders et al, 2015). As a robust
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association has yet to be identified, caution is required in
proceeding with clinical trials assessing the role of statins as novel
adjuvant agents. In addition, colorectal tumours are known to
display significant molecular heterogeneity (Ogino et al, 2012).
A molecular pathological epidemiology approach is therefore
required to determine whether the potential anti-cancer effect of
statins is confined to specific molecular subgroups (Ogino et al,
2011). Candidate mevalonate pathway biomarkers that may
differentiate tumours more likely to respond to statin therapy
include HMGCR, p53, and KRAS.
The seminal work by Freed-Pastor et al (2012) implicates the
mevalonate pathway as a potential therapeutic target for tumours
bearing mutations in TP53. They demonstrated that statins were
able to reverse the malignant phenotype of p53 mutant but not
p53 wild-type breast cancer cells in vitro. Similarly, an in vivo
breast cancer study demonstrated that the anti-proliferative effect
of statins was limited to tumours that overexpressed HMGCR
(Bjarnadottir et al, 2013). Finally, RAS signalling may be inhibited
by statin-induced depletion of downstream isoprenoids required
for posttranslational prenylation of small GTPases such as ras and
rho (Bardou et al, 2010; Ng et al, 2011; Thurnher et al, 2012).
Prenylation of k-ras makes the protein lipophilic and ensures
translocation to the cell membrane where it can exert its
proliferative effects (Konstantinopoulos et al, 2007; Krens et al,
2014). Based on this hypothesis, the effect of statins on colorectal
cancer survival may differ according to KRAS gene mutation
status (Ng et al, 2011). The aim of this study was therefore to
assess the interaction between statin use, the potential mevalonate
pathway biomarkers p53, HMGCR and KRAS, and survival in a
population-based cohort study of patients with stage II and III
colon cancer.
MATERIALS AND METHODS
Study cohort. The Northern Ireland Cancer Registry was used to
identify 1426 stage II and III colon cancer patients undergoing
surgical resection between 2004 and 2008 (Figure 1). Rectal cancers
were excluded as neoadjuvant radiotherapy could potentially alter
tumour expression profiles. Ethical approval through the Northern
Ireland Biobank (NIB reference number 13–0087) permitted
retrieval of formalin-fixed, paraffin-embedded (FFPE) tissue blocks
for patients within two of the five regional Health and Social Care
trusts. For this molecular pathological epidemiology study, the
final cohort was subsequently restricted to only include patients
within the biobank remit (n¼ 740, 51.9%). These patients were
representative of the overall Northern Ireland cohort with
respect to age, sex, stage, and adjuvant chemotherapy receipt
(Supplementary Table 1).
Clinicopathological variables and follow-up. The Clinical Oncol-
ogy Information System (COIS), a prospective electronic record of
cancer patient management, was used to collect clinical variables
including adjuvant chemotherapy use, prescription medication use,
family history of colorectal cancer and Eastern Cooperative
Oncology Group (ECOG) performance status. This process was
supplemented by a manual chart review when insufficient
information was recorded on COIS or no record was present.
Pathological variables were retrieved from full pathology reports.
Occurrence and cause of death were assessed via data linkage to the
Northern Ireland Registrar General’s Office (follow-up censored 31
December 2013). Colorectal cancer-specific deaths were defined as
those with an underlying cause of death International Classifica-
tion of Disease code C18, C19, C20 (anus), and/or C26 (other and
ill-defined digestive organs).
Drug exposure assessment. Statin exposure (user vs non-user)
based on current prescription medications was assessed at a single
perioperative time point for all patients. When medication
information was available on COIS, this time point was the initial
post-operative oncology review. When medication information
was not available on COIS, statin exposure was determined from
the post-operative hospital discharge letter. Information on
medication dosage was not consistently recorded on COIS and
therefore not considered. Information on aspirin exposure was also
assessed using these methods. Our research group has previously
demonstrated that 98.5% of aspirin prescriptions after colorectal
cancer diagnosis in the United Kingdom are for low-dose (75mg)
aspirin (Cardwell et al, 2014b). Aspirin exposure in this study is
therefore considered representative of low-dose aspirin.
Tumour molecular analysis. FFPE blocks were retrieved for
89.3% of the cohort (661 of 740). Three 1.0mm diameter tissue
cores were extracted from representative areas within donor blocks
and inserted into recipient blocks using a manual tissue arrayer
(Estigen, Tartu, and Estonia) as described previously (Zhang et al,
2003; Boyle et al, 2014). The immunohistochemistry methods for
p53 (DO-7 antibody clone to p53, Dako UK Ltd, Ely, UK—
catalogue number M7001) and HMGCR (Atlas Antibodies AB,
Stockholm, Sweden—catalogue number HPA008338) staining are
described in the Supplementary Methods. QuPath (Queen’s
University Belfast, Northern Ireland) image analysis software
facilitated digital immunoscoring (Supplementary Methods). An
H-score was calculated based on the extent and intensity of
cytoplasmic or nuclear staining where appropriate (H-score¼ 3
% of strongly staining cytoplasmþ 2% of moderately staining
cytoplasmþ 1% of weakly staining cytoplasm, giving a range of
0–300) (McCarty et al, 1986).
A three-tier scoring system was applied to differentiate normal
(non-extreme) from aberrant (extreme positive or extreme
negative) patterns of p53 expression (Figure 2). Cores were
designated as extreme negative if there was confluent negative
staining within the represented population of tumour nuclei.
Diffuse strong positivity was considered representative of extreme
positive expression and intermediate heterogeneous expression was
considered a non-extreme (normal) pattern of staining (Boyle et al,
2014). Selection and validation of the p53 cut points are described
in the Supplementary Methods. 3-Hydroxy-3-methylglutaryl
coenzyme-A reductase H-scores were categorised into tertiles for
prognostic analyses and dichotomised around the median value for
survival analyses that tested the interaction between statin use and
HMGCR expression. Representative images of HMGCR expression
are shown in Supplementary Figure 1. Based on these methods, the
final p53 and HMGCR categories were determined using the
median of the three available H-scores for each case.
Detailed methods for DNA extraction, KRAS mutation analysis,
and microsatellite instability (MSI) status using commercially
available kits are provided as Supplementary Methods. Briefly
KRAS mutation status was assessed using previously described
methods for the ColoCarta Panel (Agena Bioscience, Hamburg,
Germany; Fumagalli et al, 2010), whereas MSI status was
determined using five mononucleotide repeat markers (BAT-25,
BAT-26, NR-21, NR-24, and MONO-27).
Statistical analysis. All statistical analysis was performed using
Stata 13 (StataCorp, College Station, TX, USA). The w2-test was
used to compare characteristics between statin users and non-
users. The primary outcome of this study was colorectal cancer-
specific survival and the secondary outcome was overall
survival. The association between statin use and survival was
assessed in the whole cohort and then in analyses stratified by
biomarker status. Only cases with information on statin
exposure (known user vs known non-user) were included in
the former analysis. Only cases with available exposure
information and tissue for biomarker assessment were included
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in the subsequent stratified analyses. Other missing categorical
data were coded as unknown.
Survival analysis was performed using the Cox proportional
hazards model to calculate hazard ratios (HRs) and associated
95% confidence intervals (CIs). The multivariable models for
colorectal cancer-specific survival adjusted for age, gender, year of
diagnosis, grade, MSI status, ECOG performance status, family
history of colorectal cancer, adjuvant chemotherapy use, stage,
and aspirin use. In addition to the these variables, the overall
survival multivariable model also adjusted for Charlson Comor-
bidity Index score as a continuous variable (Khan et al, 2010).
Analyses were stratified by biomarker status. Interaction terms for
statin use and p53, HMGCR, or KRAS were then included in the
Cox model and Wald’s test was used to assess for statistical
interaction. Sensitivity analysis was performed using complete-
case data (cases with missing data were excluded). All P-values
were two-sided and a value o0.05 was considered statistically
significant.
RESULTS
Patients. Information on prescription medication use was avail-
able for 91.9% (n¼ 680) of patients in this population-based
cohort study. Overall, 25.3% (n¼ 172) used statins. Compared
with those with available information on medication use, patients
with no information on medication use were older and more likely
to be diagnosed in the earlier years of the study. However, there
was no difference in stage, grade of tumour differentiation, or MSI
status (Supplementary Table 2). After a mean follow-up of 5.7
years (range 0–10), there were 299 all-cause and 212 colorectal
cancer-specific deaths among these patients.
Statin use and survival. Table 1 summarises the baseline
characteristics between statin users and non-users. Statin users
were more likely to be older, male, and diagnosed later in the
cohort compared with statin non-users. Statin users were also more
All stage II and III colon cancer (ICD-
code C18) patients in Northern
Ireland Cancer Registry (2004–2008)
n=1862
Patients excluded following clinical note
review (n=113):
Duplicate patient (n=1)
Upstaged to stage IV (n=86)
Downstaged to stage I (n=9)
Received neoadjuvant therapy for rectal
tumour (n=9)
Appendiceal tumour (n=7)
TxN0 stoma mucocutaneous junction
tumour (n=1)
Colon adenocarcinoma patients only
n=1824
Underwent a surgical resection
n=1539
Patients meeting selection criteria
n=1426
Patients not within NIB remit
n=686
Information on prescription medication use
available
n=680
Tissue microarrays created and information
on prescription medication use available
n=603
HMGCR and p53 immunohistochemical
expression assessed
n=603
Patients within NIB remit
n=740
Resection specimen tumour blocks
retrieved
n=661
Extracted DNA and information on
prescription medication use available
n=599
KRAS mutation status assessed
n=594
Figure 1. Selection of stage II and III colon cancer (adenocarcinoma) patients and samples. ICD¼ International Classification of Disease;
NIB¼Northern Ireland Biobank.
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likely to concomitantly use aspirin. There were a smaller
proportion of MSI-high tumours among statin users but the
proportion of patients with unknown MSI status was higher in
statin non-users. However, there was no difference in tumour
differentiation grade, stage, or the proportion of patients receiving
adjuvant chemotherapy between users and non-users. There was
also no difference in the proportion of right-sided tumours in
statin users compared with non-users (58.1 vs 56.1%).
Statin use at the time of diagnosis was not associated with a
significant reduction in colorectal cancer-specific (adjusted
HR¼ 0.91, 95% CI 0.64–1.28) or overall mortality (adjusted
HR¼ 0.83, 95% CI 0.61–1.12) compared with non-use (Table 2).
Immunohistochemical expression of p53. In total, n¼ 361
(59.9%) tumours demonstrated an aberrant pattern of p53
immunostaining (extreme positive or extreme negative). The
proportion of tumours with aberrant patterns of p53 immunos-
taining was similar between statin users and statin non-users
(59.1 vs 62.0%, P¼ 0.52). Compared with wild-type p53 expres-
sion, aberrant p53 immunostaining was associated with a 53%
increase in hazard for unadjusted colorectal cancer-specific
mortality (HR¼ 1.53, 95% CI 1.13–2.09). However, this association
was attenuated when potential confounding variables were
included in the multivariable model (adjusted HR¼ 1.38, 95% CI
0.97–1.95, Table 2).
In stratified analysis, there was no evidence that the association
between statin use and colorectal cancer-specific survival differed
by p53 immunostaining patterns (wild-type adjusted HR¼ 1.31,
95% CI 0.67–2.56 vs aberrant adjusted HR¼ 0.80, 95% CI 0.52–
1.24). Similar results were observed for overall survival (Table 3).
3-Hydroxy-3-methylglutaryl coenzyme-A reductase immunohis-
tochemical expression. Statin users were more likely to have
tumours in the highest HMGCR tertile compared with non-users
(43.7 vs 30.8%, P¼ 0.01). As shown in Table 2, however, there was
no evidence that higher levels of HMGCR expression were
associated with significantly better colorectal cancer-specific or
overall survival (adjusted P for trend¼ 0.18 and 0.12, respectively).
There was no evidence of significant associations with colorectal
cancer-specific survival among statin users compared with non-
users when the cohort was stratified by tumour HMGCR
expression level, although the direction of HRs did differ
(HMGCR-high adjusted HR¼ 0.69, 95% CI 0.40–1.18 vs
HMGCR-low adjusted HR¼ 1.10, 95% CI 0.66–1.84). Similarly,
there was no evidence of a differential benefit for overall survival in
statin users compared with non-users when the cohort was
stratified by HMGCR status (Table 3).
KRAS mutations. KRAS mutation status (mutant vs wild-type)
was available for 99.2% of these samples with extracted DNA (594
of 599). Statin users had slightly less KRAS mutant tumours
compared with statin non-users, although the difference was not
statistically significant (34.0 vs 40.2%, P¼ 0.17). Compared with
wild-type KRAS, the presence of a KRAS mutation was not
associated with significantly worse colorectal cancer-specific
survival (adjusted HR¼ 1.12, 95% CI 0.82–1.53, Table 2).
There was no evidence of an improvement in colorectal cancer-
specific survival among statin users compared with non-users
when the cohort was stratified by KRAS mutation status, although
again the direction of effect differed between wild-type and mutant
KRAS tumours (KRAS wild-type adjusted HR¼ 0.73, 95% CI
0.44–1.19 vs KRAS mutant tumour adjusted HR¼ 1.21, 95% CI
0.70–2.21). Similar nonsignificant results were observed for overall
survival (Table 3).
Sensitivity analysis. In general, the associations described above
were not markedly altered when a complete case data set (n¼ 372)
was used (Table 4). There was some evidence though that statin use
was associated with improved colorectal cancer-specific survival in
tumours that had higher levels of HMGCR expression (HMGCR-
A
D E F
B C
Figure 2. p53 immunohistochemistry in colon cancer tissue microarrays and associated markup for digital immunoscoring using QuPath image
analysis software. Detected cells are colour-coded according to their classification: green¼non-tumour; blue¼negatively staining tumour;
yellow¼weakly staining tumour; orange¼moderately staining tumour; red¼ strongly staining tumour. (A) Original core from a tumour
demonstrating aberrant negative p53 immunostaining. (B) Original core from a tumour deomonstrating non-extreme (normal) p53
immunostaining. (C) Original core from a tumour demonstrating aberrant positive p53 immunostaining. (D) QuPath cellular markup in the aberrant
negative p53 core. (E) QuPath cellular markup in the non-extreme (normal) p53 core. (F) QuPath cellular markup in the aberrant positive p53 core.
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high adjusted HR¼ 0.51, 95% CI 0.26–0.97 vs HMGCR-low
adjusted HR¼ 0.92, 95% CI 0.45–1.87, P for interaction¼ 0.05).
Previously observed null associations by KRAS status and p53
expression remained. All associations became attenuated in
analyses evaluating overall survival.
DISCUSSION
In this population-based cohort study of stage II and III colon
cancer, perioperative statin prescription was not associated with
significantly improved colorectal cancer-specific survival. Similarly,
statin use was not associated with better colorectal cancer-specific
or overall survival when the cohort was stratified by tumour
biomarkers related to the mevalonate pathway.
The HR for the association between statin use and cancer-
specific survival in this cohort was similar to that reported in a
recent meta-analysis of colorectal cancer observational studies.
(Gray et al, 2016) The pooled estimate from four studies assessing
post-diagnostic statin use was nonsignificant, despite including
over 19 000 patients. It also suggests that the effect of any
association is only likely to be moderate at best (pooled HR¼ 0.84,
95% CI 0.68–1.04). Despite optimistic pre-clinical data, these
findings confirm the need to evaluate biomarkers that may identify
tumours more likely to respond to the potential anti-cancer effects
of statins.
This is the first study to assess the interaction between statin use
and HMGCR expression in colon cancer. Statin users had a higher
proportion of tumours in the highest HMGCR tertile, although
statin-induced inhibition of the mevalonate pathway is known to
trigger a marked increase in the production of inactive HMGCR
in vitro (Goldstein and Brown, 1990; Bengtsson et al, 2014). In the
main analysis, there was no evidence that statin users had better
survival compared with non-users in tumours with higher levels of
HMGCR expression. However, in the complete-case subgroup
analysis, which excluded cases with any missing data, statin use
was associated with better cancer-specific survival in tumours with
higher levels of HMGCR expression. This result should be
interpreted with caution though, as multiple hypotheses were
tested. Further exploration in additional molecular pathological
epidemiology cohorts should be considered, as the complete-case
subgroup analysis results are in line with an in vivo breast cancer
study, which suggests that statins may have an anti-proliferative
effect in tumours that overexpress HMGCR. (Bjarnadottir et al,
2013).
Overexpression of HMGCR has been proposed to be prognostic
in a number of malignancies including breast (Borgquist et al,
2008; Brennan et al, 2011) and epithelial ovarian cancer (Brennan
et al, 2010). However, a recent population-based breast cancer
cohort study failed to demonstrate that overexpression of HMGCR
was associated with better survival (Gustbe´e et al, 2015). Similarly,
overexpression of HMGCR was not associated with improved
survival after adjusting for confounding variables in colorectal
cancer cases within the Malmo¨ Diet and Cancer Study (Bengtsson
et al, 2014). The present study largely corroborates this finding.
To the best of the authors’ knowledge, this is the first study to
assess the interaction between statin use, p53 expression, and
survival in patients with colon cancer. A significant interaction was
not identified in this instance, but further work is required as
TP53 mutation status was not directly assessed. Missense
TP53 mutations result in stabilization of an inactive form of p53
resulting in nuclear accumulation and a correlation with the
aberrant positive pattern of expression (Kaye et al, 2010;
McCluggage et al, 2011). Only more recently has it been widely
appreciated that the aberrant negative pattern of p53 staining is a
distinct entity and not part of the spectrum of wild-type staining
(Boyle et al, 2014). This pattern of staining may be attributed to a
null TP53 mutation resulting in complete absence of the detectable
protein (Ko¨bel et al, 2010). Importantly though, these patterns
should be viewed as a spectrum of functional protein status rather
than as a surrogate for TP53 mutation status as epigenetic silencing
may also contribute to aberrant negative expression (Kaye et al,
2010; Boyle et al, 2014). On this basis, mevalonate pathway gene-
expression upregulation associated with mutant p53 (Freed-Pastor
et al, 2012) may be specific to mutations of TP53 rather than to
alternate circumstances resulting in aberrant expression of the
protein. Future studies should therefore assess the interaction
between the presence of TP53 mutations, statin use, and colon
Table 1. Clinical and demographic characteristics according
to statin use
Characteristic
Statin non-user
(n¼508) number
(%)
Statin user
(n¼172) number
(%) P-value
Age category
o50 44 (8.7) 3 (1.7) 0.001
50–o60 61 (12.0) 10 (5.8)
60–o70 134 (26.4) 63 (36.6)
70–o80 173 (34.1) 66 (38.4)
480 96 (18.9) 30 (17.4)
Gender
Male 265 (52.2) 105 (61.1) 0.04
Female 243 (47.8) 67 (39.0)
Year of diagnosis
2004 77 (15.2) 24 (14.0) 0.003
2005 116 (22.8) 18 (10.5)
2006 98 (19.3) 33 (19.2)
2007 104 (20.5) 42 (24.4)
2008 113 (22.2) 55 (32.0)
Stage
II 290 (57.1) 99 (57.6) 0.91
III 218 (42.9) 73 (42.4)
Grade
Well-moderate 429 (84.5) 148 (86.1) 0.88
Poor 76 (15.0) 23 (13.4)
Unknown 3 (0.6) 1 (0.6)
Location
Right colon 285 (56.1) 100 (58.14) 0.62
Left colon 218 (42.9) 69 (40.1)
Not specified 5 (1.0) 3 (1.7)
MSI status
Non MSI-high 312 (61.4) 125 (72.7) 0.02
MSI-high 96 (18.9) 27 (15.7)
Unknown 100 (19.7) 20 (11.6)
Adjuvant chemotherapy
No 332 (65.4) 123 (71.5) 0.14
Yes 176 (34.7) 49 (28.5)
ECOG performance status
0–1 285 (56.1) 87 (50.6) 0.10
2 30 (5.9) 17 (9.9)
3–4 20 (3.9) 12 (7.0)
Unknown 173 (34.1) 56 (32.6)
Family history of colorectal cancer
Yes 276 (54.3) 91 (52.9) 0.85
No 78 (15.4) 25 (14.5)
Unknown 154 (30.3) 56 (32.6)
Aspirin use
Non-user 435 (85.6) 99 (57.6) o0.001
User 73 (14.4) 73 (42.4)
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; MSI¼microsatellite
instability.
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cancer survival before excluding the potential relevance of this
biomarker.
Finally, statin use was not associated with improved colorectal
cancer-specific or overall survival when the cohort was stratified by
KRAS mutation status. This finding is consistent with results from
a cohort of 394 patients enrolled in a chemotherapy clinical trial
(CALGB 89803; Ng et al, 2011) and 1209 patients within a German
population-based colorectal cancer cohort (Hoffmeister et al,
2015). Similarly, statin use was not associated with improved
progression free survival in cetuximab treated metastatic colorectal
cancer patients within the CAIRO2 trial, irrespective of KRAS
mutation status (Krens et al, 2014). The median progression-free
survival was also similar between the statin and placebo arms of a
subgroup of 83 patients with KRAS mutant tumours in a
randomised controlled trial of XELIRI/FOLFIRI±simvastatin in
patients with metastatic colorectal cancer (Lim et al, 2015).
A major strength of this study is the inclusion of population-
representative colon cancer patients. Application of a precise,
automated, and validated digital immunoscoring system also
ensures robust immunoexpression data that are highly reprodu-
cible. As with all observational studies, however, there may be
residual confounding that we were not able to control. A more
specific limitation is that data on statin prescription was also only
available at a single perioperative time point and this may not
reflect changes in post-diagnostic use (Paleari et al, 2016).
However, a similar European colorectal cancer cohort demon-
strated 88% concordance between baseline and long-term statin
use (Hoffmeister et al, 2015). Statin use at this time could also alter
tumour behaviour, as it has previously been reported that pre-
diagnostic statin users were less likely to develop KRAS wild-type
tumours (Lee et al, 2011). In the current study the opposite
association (non-significant) was observed with a lower proportion
Table 2. Colorectal cancer-specific and overall survival according to statin use, p53 and HMGCR immunohistochemistry, and
KRAS mutation status
Colorectal cancer-specific survival Overall survival
Characteristic
No. of CRC
deaths/at
risk
Unadjusted
HR
(95% CI) P-value
Adjusted
HR
(95% CI)a P-value
No. of
deaths/
at risk
Unadjusted
HR
(95% CI) P-value
Adjusted
HR
(95% CI)b P-value
All participants
Statin non-user 163/508 1 (Reference) 1 (Reference) 227/508 1 (Reference) 1 (Reference)
Statin user 49/172 0.90 (0.65–1.24) 0.51 0.91 (0.64–1.28) 0.58 72/172 0.96 (0.74–1.25) 0.76 0.83 (0.61–1.12) 0.22
Patterns of p53 immunostaining
Normal 59/242 1 (Reference) 1 (Reference) 97/242 1 (Reference) 1 (Reference)
Aberrant 128/361 1.53 (1.13–2.09) 0.007 1.38 (0.97–1.95) 0.07 173/361 1.27 (0.99–1.62) 0.06 1.13 (0.85–1.49) 0.41
HMGCR tertiles
1 (lowest) 72/197 1 (Reference) 1 (Reference) 102/197 1 (Reference) 1 (Reference)
2 61/200 0.84 (0.60–1.19) 0.33 0.84 (0.58–1.21) 0.35 91/200 0.91 (0.69–1.21) 0.53 0.89 (0.66–1.21) 0.47
3 (highest 55/206 0.73 (0.51–1.04) 0.08 0.76 (0.51–1.14) 0.18 78/206 0.76 (0.56–1.02) 0.07 0.77 (0.55–1.07) 0.12
KRAS
Wild-type 109/365 1 (Reference) 1 (Reference) 156/365 1 (Reference) 1 (Reference)
Mutated 76/229 1.16 (0.86–1.55) 0.33 1.12 (0.82–1.53) 0.49 111/229 1.18 (0.92–1.51) 0.18 1.14 (0.88–1.48) 0.32
Abbreviations: CI¼ confidence interval; CRC¼ colorectal cancer; ECOG¼Eastern Cooperative Oncology Group; HR¼ hazard ratio; MSI¼microsatellite instability.
aMultivariable model adjusted for age, gender, year of diagnosis, grade, MSI status, ECOG performance status, family history of colorectal cancer, adjuvant chemotherapy use, stage, and
aspirin use.
bMultivariable model adjusted for all variables in footnote a and also adjusted for Charlson Comorbidity Index score.
Table 3. Statin use and colorectal cancer-specific / overall survival stratified by biomarker subgroups
Colorectal cancer-specific survival Overall survival
Statin
non-
user
Statin
user
HR (95%CI)a
user vs
non-user P-value
P for
interaction
Statin
non-user
Statin
user
HR (95%CI)b
user vs non-
user P-value
P for
interaction
No. of deaths/
patients
No. of deaths/
patients
Stratified by patterns of p53 immunostaining
Normal 43/182 16/60 1.31 (0.67–2.56) 0.43 0.51 75/182 22/60 0.67 (0.34–1.30) 0.24 0.60
Aberrant 98/263 30/98 0.80 (0.52–1.24) 0.33 127/263 46/98 0.91 (0.63–1.32) 0.61
Stratified by HMGCR expression
H-score omedian 79/231 26/69 1.10 (0.66–1.84) 0.71 0.08 118/231 34/69 0.78 (0.49–1.25) 0.30 0.28
H-score Xmedian 63/214 20/89 0.69 (0.40–1.18) 0.17 85/214 34/89 0.77 (0.49–1.22) 0.26
Stratified by KRAS mutation status
Wild-type 83/262 26/103 0.73 (0.44–1.19) 0.20 0.05 116/262 40/103 0.68 (0.44–1.04) 0.08 0.07
Mutated 57/176 19/53 1.21 (0.70–2.21) 0.50 84/176 27/53 1.00 (0.61–1.66) 0.98
Abbreviations: CI¼ confidence intervals; ECOG¼Eastern Cooperative Oncology Group; HR¼ hazard ratio; MSI¼microsatellite instability.
aMultivariable model adjusted for age, gender, year of diagnosis, grade, MSI status, ECOG performance status, family history of colorectal cancer, adjuvant chemotherapy use, stage, and
aspirin use.
bMultivariable model adjusted for all variables in footnote a and also adjusted for Charlson Comorbidity Index score.
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of KRAS mutant tumours among statin users. Importantly though,
assessing medication use at a fixed time point excludes immortal
time bias (Le´vesque et al, 2010). The assessment of Ras status was
limited to exons 2 and 3 of KRAS in this study. Misclassification
could occur for other mutations of KRAS or NRAS, although
overall these mutations are uncommon (o3%), and it is unlikely
that this would greatly alter the stratified analysis.
A further limitation is that information on the type and dose of
statin prescribed was not available. It has previously been
hypothesised that the potential anti-cancer effect of statins is restricted
to lipophilic statins (Ahern et al, 2014). In addition, the serum statin
concentrations achieved with cardiovascular protective doses of the
medication (e.g., simvastatin 40mg) may not be sufficient to induce
the anti-cancer effects observed in preclinical studies (Lim et al, 2015).
Finally, despite being population-based, this study lacks power to
definitively investigate the interaction between the proposed meva-
lonate pathway biomarkers, statin use, and colon cancer survival.
In summary, statin use was not associated with better survival in
this population-based colon cancer cohort study. In keeping with
previous studies, a survival benefit for statin use was not apparent
after stratification by tumour KRAS mutation status. Similar
results were also observed for p53 immunohistochemical status
but additional studies should assess TP53 mutation status as a
potential biomarker. There was some evidence of a difference in
association between statin use and colon cancer survival by
tumour HMGCR expression. In general though, this finding was
inconsistent and requires further investigation in additional large
studies.
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